CJC-1295, IPAMORELIN 10/10 (BLEND)

Overview of CJC-1295, Ipamorelin 10/10 (Blend)

CJC-1295, Ipamorelin 10/10 (Blend) is a balanced dual-receptor research formulation designed for laboratory evaluation of coordinated somatotropic signaling. By combining a GHRH receptor agonist with a selective GHS-R1a agonist at equal 10mg/10mg strength, this blend enables structured investigation of integrated growth hormone axis activation within controlled in vitro models.

The 10/10 ratio provides an increased total peptide concentration compared to 5/5 formulations, supporting research requiring extended receptor occupancy modeling or higher-concentration pathway analysis under controlled experimental conditions.

This blend is supplied in lyophilized sterile powder form and is intended strictly for laboratory research and analytical applications.

Molecular and Receptor Pharmacology

CJC-1295 (Mod GRF 1–29)

CJC-1295 no DAC is a modified GHRH analog engineered to bind selectively to the GHRH receptor (GHRH-R). In laboratory systems, activation of this receptor stimulates:

• Adenylate cyclase activation

• Increased cyclic AMP (cAMP) production

• Protein kinase A (PKA) signaling

• Transcriptional regulation within somatotropic pathways

The no DAC format allows pulsatile receptor engagement modeling in controlled research environments.

Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that binds to the GHS-R1a receptor. In experimental systems, Ipamorelin activates:

• Gq/11-mediated phospholipase C signaling

• Inositol triphosphate (IP3) generation

• Intracellular calcium mobilization

• Protein kinase C pathway engagement

Ipamorelin is frequently referenced for its receptor selectivity in comparative ghrelin receptor pharmacology studies.

Dual-Pathway Signaling in Laboratory Models

CJC-1295, Ipamorelin 10/10 (Blend) enables simultaneous activation of:

1. GHRH receptor pathway (cAMP/PKA mediated)

2. GHS-R1a receptor pathway (PLC/Ca²⁺ mediated)

This dual stimulation allows researchers to evaluate:

• Growth hormone pulsatility simulation models

• Signal amplification dynamics

• Intracellular cascade integration

• Receptor cross-talk mechanisms

• Hypothalamic–pituitary axis coordination

The complementary nature of these pathways provides a structured framework for examining endocrine signaling integration within laboratory environments.

Research Applications

CJC-1295, Ipamorelin 10/10 (Blend) is frequently used in laboratory investigations involving:

• Somatotropic axis modeling

• Dual receptor pharmacology research

• Intracellular second messenger pathway analysis

• Growth hormone pulsatility research models

• Endocrine signaling integration studies

• Comparative secretagogue pathway evaluation

Researchers studying GHRH and GHS receptor signaling often reference peer-reviewed scientific databases such as the National Center for Biotechnology Information (NCBI) for foundational literature.

Stability and Laboratory Handling

CJC-1295, Ipamorelin 10/10 (Blend) is supplied in lyophilized form to preserve structural stability and prevent hydrolytic degradation prior to reconstitution.

Laboratory handling recommendations:

• Store under refrigerated conditions

• Avoid repeated freeze–thaw cycles

• Reconstitute with sterile laboratory-grade solvent

• Follow institutional peptide handling protocols

Lyophilization ensures reproducible peptide stability across experimental applications.

Product Specifications

• Compounds: CJC-1295 (No DAC) + Ipamorelin

• Ratio: 10mg / 10mg

• Classification: Dual growth hormone research peptide blend

• Form: Lyophilized sterile powder

• Appearance: White to off-white solid

• Storage: Refrigerated conditions recommended

• Intended Use: Laboratory research only

Analytical Verification

Each batch undergoes analytical verification to confirm peptide identity and purity, including:

• High-performance liquid chromatography (HPLC)

• Mass spectrometry analysis

• Structural validation

• Batch-to-batch consistency testing

Lot numbers are assigned for traceability within formal research documentation systems.

Compliance Notice

CJC-1295, Ipamorelin 10/10 (Blend) is intended strictly for laboratory research use.

This product is not approved for human consumption, therapeutic application, or clinical use. It is sold exclusively for in vitro research, analytical testing, and scientific investigation by qualified professionals.